Mylan Company Profile (NASDAQ:MYL)

About Mylan

Mylan logoMylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: MYL
  • CUSIP: 62853010
Key Metrics:
  • Previous Close: $41.31
  • 50 Day Moving Average: $43.98
  • 200 Day Moving Average: $44.67
  • 52-Week Range: $37.59 - $55.51
  • Trailing P/E Ratio: 26.15
  • Foreward P/E Ratio: 7.17
  • P/E Growth: 0.65
  • Market Cap: $22.10B
  • Outstanding Shares: 534,911,000
  • Beta: 1.25
Profitability:
  • Net Margins: 8.11%
  • Return on Equity: 23.22%
  • Return on Assets: 9.82%
Debt:
  • Debt-to-Equity Ratio: 1.24%
  • Current Ratio: 3.23%
  • Quick Ratio: 2.65%
Additional Links:
Companies Related to Mylan:

Analyst Ratings

Consensus Ratings for Mylan (NASDAQ:MYL) (?)
Ratings Breakdown: 8 Hold Ratings, 8 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.59)
Consensus Price Target: $55.07 (33.30% upside)

Analysts' Ratings History for Mylan (NASDAQ:MYL)
Show:
DateFirmActionRatingPrice TargetDetails
9/22/2016Leerink SwannReiterated RatingBuyView Rating Details
9/22/2016ArgusSet Price TargetBuy$55.00View Rating Details
9/23/2016Sanford C. BernsteinSet Price TargetBuy$60.00View Rating Details
9/23/2016Deutsche Bank AGSet Price TargetBuy$60.00 -> $58.00View Rating Details
9/6/2016RBC Capital MarketsLower Price TargetSector Perform$52.00 -> $48.00View Rating Details
9/6/2016Royal Bank Of CanadaLower Price TargetSector Perform$52.00 -> $48.00View Rating Details
9/4/2016Wells Fargo & Co.Set Price TargetHold$44.00View Rating Details
8/30/2016BTIG ResearchReiterated RatingBuy$60.00View Rating Details
8/26/2016Evercore ISIReiterated RatingHold$49.00View Rating Details
8/25/2016Goldman Sachs Group Inc.Reiterated RatingConviction-Buy$60.00View Rating Details
8/24/2016Bank of America Corp.Reiterated RatingBuy$70.00View Rating Details
7/12/2016Morgan StanleyReiterated RatingHoldView Rating Details
6/25/2016JPMorgan Chase & Co.Reiterated RatingOverweightView Rating Details
2/11/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
2/11/2016GuggenheimReiterated RatingNeutralView Rating Details
2/11/2016Cowen and CompanyLower Price TargetMarket Perform$65.00 -> $55.00View Rating Details
11/16/2015BMO Capital MarketsLower Price TargetMarket Perform$46.00View Rating Details
9/21/2015Barclays PLCInitiated CoverageEqual Weight$57.00View Rating Details
8/26/2015Standpoint ResearchInitiated CoverageBuy$70.00View Rating Details
8/12/2015SusquehannaLower Price TargetPositive$85.00 -> $68.00View Rating Details
6/18/2015B. RileyInitiated CoverageBuy$85.00 -> $71.23View Rating Details
6/3/2015Raymond James Financial Inc.Initiated CoverageMarket PerformView Rating Details
4/22/2015CRT CapitalBoost Price TargetBuy$68.00 -> $87.00View Rating Details
10/6/2014S&P Equity ResearchReiterated RatingBuyView Rating Details
10/6/2014ING GroupReiterated RatingBuy$68.00View Rating Details
(Data available from 9/27/2014 forward)

Earnings

Earnings History for Mylan (NASDAQ:MYL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/28/2016        
8/9/2016Q216$1.13$1.16$2.58 billion$2.56 billionViewN/AView Earnings Details
5/3/2016Q116$0.74$0.76$2.23 billion$2.19 billionViewN/AView Earnings Details
2/10/2016Q415$1.27$1.22$2.71 billion$2.49 billionViewListenView Earnings Details
10/30/2015Q315$1.38$1.43$2.79 billion$2.71 billionViewListenView Earnings Details
8/6/2015Q215$0.89$0.91$2.39 billion$2.37 millionViewN/AView Earnings Details
5/5/2015Q115$0.69$0.70$1.87 billionViewListenView Earnings Details
3/2/2015Q414$1.05$1.05$2.07 billion$2.08 billionViewListenView Earnings Details
10/30/2014Q314$1.14$1.16$2.06 billion$2.08 billionViewN/AView Earnings Details
8/7/2014Q214$0.73$0.69$1.88 billion$1.84 billionViewN/AView Earnings Details
5/1/2014Q114$0.68$0.66$1.80 billion$1.72 billionViewN/AView Earnings Details
2/27/2014Q413$0.75$0.78$1.81 billion$1.81 billionViewN/AView Earnings Details
10/31/2013Q313$0.79$0.82$1.84 billion$1.77 billionViewN/AView Earnings Details
8/1/2013Q2 2013$0.67$0.68$1.73 billion$1.70 billionViewN/AView Earnings Details
5/2/2013Q1 2013$0.62$0.62$1.69 billion$1.63 billionViewN/AView Earnings Details
2/27/2013Q4 2012$0.64$0.65$1.73 billion$1.72 billionViewN/AView Earnings Details
10/25/2012$0.77$0.83ViewN/AView Earnings Details
7/26/2012$0.55$0.60ViewN/AView Earnings Details
4/26/2012$0.51$0.52ViewN/AView Earnings Details
2/21/2012$0.50$0.53ViewN/AView Earnings Details
10/26/2011$0.51$0.55ViewN/AView Earnings Details
7/27/2011$0.45$0.52ViewN/AView Earnings Details
5/3/2011$0.44$0.44ViewN/AView Earnings Details
2/24/2011$0.45$0.45ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Mylan (NASDAQ:MYL)
Current Year EPS Consensus Estimate: $4.96 EPS
Next Year EPS Consensus Estimate: $5.76 EPS

Dividends

Dividend History for Mylan (NASDAQ:MYL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Mylan (NASDAQ:MYL)
Insider Ownership Percentage: 0.71%
Institutional Ownership Percentage: 60.20%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/9/2016Heather M BreschCEOSell100,200$50.00$5,010,000.00View SEC Filing  
6/3/2016Joseph C Md MaroonDirectorBuy1,670$44.95$75,066.50View SEC Filing  
5/25/2016Robert J CindrichDirectorBuy1,190$42.47$50,539.30View SEC Filing  
5/12/2016Melina E HigginsDirectorBuy19,900$38.68$769,732.00View SEC Filing  
5/6/2016Melina E HigginsDirectorBuy100$38.69$3,869.00View SEC Filing  
4/28/2016Melina E HigginsDirectorBuy35,000$42.92$1,502,200.00View SEC Filing  
4/5/2016Robert J CouryChairmanSell217,755$45.96$10,008,019.80View SEC Filing  
3/31/2016Joseph C Md MaroonDirectorBuy4,337$46.36$201,063.32View SEC Filing  
3/17/2016Mark W ParrishDirectorBuy1,705$44.00$75,020.00View SEC Filing  
3/8/2016Wendy CameronDirectorBuy2,190$45.69$100,061.10View SEC Filing  
3/3/2016Robert J CindrichDirectorBuy2,187$45.83$100,230.21View SEC Filing  
12/17/2015John D. SheehanCFOSell34,579$55.03$1,902,882.37View SEC Filing  
6/15/2015Melina E HigginsDirectorSell8,351$73.08$610,291.08View SEC Filing  
2/3/2015Anthony MauroInsiderSell13,255$53.15$704,503.25View SEC Filing  
2/3/2015Heather M BreschCEOSell411,996$53.15$21,897,587.40View SEC Filing  
2/3/2015Rajiv MalikPresidentSell285,394$53.15$15,168,691.10View SEC Filing  
2/3/2015Robert J CouryChairmanSell947,119$52.55$49,771,103.45View SEC Filing  
2/3/2015Rodney L PiattDirectorSell46,000$53.15$2,444,900.00View SEC Filing  
11/26/2014John D SheehanCFOSell19,475$57.50$1,119,812.50View SEC Filing  
11/25/2014Heather M BreschCEOSell100,000$55.80$5,580,000.00View SEC Filing  
11/25/2014Rajiv MalikPresidentSell120,000$55.78$6,693,600.00View SEC Filing  
11/25/2014Robert J CouryChairmanSell165,700$55.78$9,242,746.00View SEC Filing  
11/24/2014Heather M BreschCEOSell80,222$55.86$4,481,200.92View SEC Filing  
11/24/2014Rajiv MalikPresidentSell84,300$55.86$4,708,998.00View SEC Filing  
11/24/2014Robert J CouryChairmanSell105,800$55.88$5,912,104.00View SEC Filing  
11/7/2014Melina E HigginsDirectorBuy14,000$52.45$734,300.00View SEC Filing  
9/18/2014Neil F DimickDirectorSell5,432$48.26$262,148.32View SEC Filing  
6/19/2014Neil F DimickDirectorSell5,432$50.81$275,999.92View SEC Filing  
4/22/2014Rajiv MalikPresidentSell80,000$50.00$4,000,000.00View SEC Filing  
4/14/2014Heather BreschCEOSell75,000$46.07$3,455,250.00View SEC Filing  
3/20/2014Neil DimickDirectorSell5,813$53.08$308,554.04View SEC Filing  
3/14/2014C ToddDirectorSell10,000$53.00$530,000.00View SEC Filing  
3/6/2014Harry KormanCOOSell31,970$54.54$1,743,643.80View SEC Filing  
3/3/2014Anthony MauroInsiderSell20,000$54.81$1,096,200.00View SEC Filing  
3/3/2014Daniel Rizzo, Jr.CAOSell8,003$55.50$444,166.50View SEC Filing  
3/3/2014Douglas LeechDirectorSell10,000$55.40$554,000.00View SEC Filing  
1/2/2014Neil DimickDirectorSell5,813$43.15$250,830.95View SEC Filing  
12/19/2013Rodney PiattDirectorSell10,000$41.84$418,400.00View SEC Filing  
12/12/2013Daniel Rizzo, Jr.CAOSell70,683$42.04$2,971,513.32View SEC Filing  
12/12/2013Melina HigginsDirectorBuy5,000$42.03$210,150.00View SEC Filing  
9/6/2013Heather M BreschCEOSell160,000$35.35$5,656,000.00View SEC Filing  
6/3/2013Neil F DimickDirectorSell19,994$30.51$610,016.94View SEC Filing  
11/27/2012Daniel C Rizzo JrCAOSell161,124$27.28$4,395,462.72View SEC Filing  
11/2/2012Douglas J LeechDirectorSell44,280$25.94$1,148,623.20View SEC Filing  
11/1/2012Anthony MauroInsiderSell12,301$25.79$317,242.79View SEC Filing  
10/5/2012Anthony MauroInsiderSell12,296$24.84$305,432.64View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Mylan (NASDAQ:MYL)
DateHeadline
livemint.com logoMylan, Lupin said to weigh bids for Bayer dermatology business (NASDAQ:MYL)
www.livemint.com - September 27 at 6:11 PM
bloomberg.com logoMylan, Lupin Said to Weigh Bids for Bayer Dermatology Unit (NASDAQ:MYL)
www.bloomberg.com - September 27 at 6:11 PM
schaeffersresearch.com logoScandal-Plagued Mylan NV's (MYL) Potential M&A Play (NASDAQ:MYL)
www.schaeffersresearch.com - September 27 at 6:11 PM
News IconMylan CEO misled lawmakers about EpiPen profits—they’re 66% higher (NASDAQ:MYL)
arstechnica.com - September 27 at 6:11 PM
reuters.com logoMylan faces scrutiny over EpiPen profit data shown to Congress (NASDAQ:MYL)
in.reuters.com - September 27 at 6:11 PM
finance.yahoo.com logoDrug Price Bubble A Result Of Decade-Long Economic Policy Issues (NASDAQ:MYL)
finance.yahoo.com - September 27 at 6:11 PM
investorplace.com logoMylan NV (MYL) Scandal Taking Down the Generic Drug Sector (NASDAQ:MYL)
investorplace.com - September 27 at 11:03 AM
realistinvestor.com logoMylan Inc. (NASDAQ:MYL) Mean Price Target At $55.857 - RealistInvestor.com (NASDAQ:MYL)
www.realistinvestor.com - September 27 at 10:53 AM
News IconMylan CEO misled lawmakers about EpiPen profits—they're 66% higher - Ars Technica (NASDAQ:MYL)
arstechnica.com - September 27 at 10:53 AM
finance.yahoo.com logoBill George on drug pricing: I want a market-based soluti... (NASDAQ:MYL)
finance.yahoo.com - September 27 at 10:53 AM
investorplace.com logo3 Stocks to Watch Tuesday: Kite Pharma Inc (KITE), Array Biopharma Inc (ARRY) and Mylan NV (MYL) (NASDAQ:MYL)
investorplace.com - September 27 at 9:21 AM
streetinsider.com logoAllergan (AGN), Mylan (MYL) Sees Short Interest Rise, Gilead (GILD) Fall in Pharma Sector - Guggenheim - StreetInsider.com (NASDAQ:MYL)
www.streetinsider.com - September 26 at 6:19 PM
seekingalpha.com logo2 Takeaways From The Mylan Congressional EpiPen Hearing - Seeking Alpha (NASDAQ:MYL)
seekingalpha.com - September 26 at 6:19 PM
finance.yahoo.com logoKite Pharma gets good news on lymphoma treatment (NASDAQ:MYL)
finance.yahoo.com - September 26 at 6:19 PM
finance.yahoo.com logoRep. Cummings: Don't believe Mylan's numbers this year (NASDAQ:MYL)
finance.yahoo.com - September 26 at 6:19 PM
thestreet.com logoMylan (MYL) Accounted for a U.S. Tax Rate in the Profitability of the EpiPen. (NASDAQ:MYL)
www.thestreet.com - September 26 at 6:19 PM
feeds.benzinga.com logoEpipen's Profits Are Actually A Lot Higher Than Mylan Originally Told Congress (NASDAQ:MYL)
feeds.benzinga.com - September 26 at 12:56 PM
wsj.com logoMylan's EpiPen Profit 60% Higher Than Told to Congress - Wall Street Journal (NASDAQ:MYL)
www.wsj.com - September 26 at 12:56 PM
News IconCongress Absolutely Unloads On Epipen CEO (NASDAQ:MYL)
thelakeandeswave.com - September 26 at 11:01 AM
reuters.com logoPfizer says not to split into two (NASDAQ:MYL)
www.reuters.com - September 26 at 11:01 AM
marketrealist.com logoAnd Then There’s Mylan’s Specialty Segment, Home of the EpiPen (NASDAQ:MYL)
marketrealist.com - September 26 at 11:01 AM
marketrealist.com logoTeva Pharmaceutical Leads in Global Generic Pharmaceutical Space (NASDAQ:MYL)
marketrealist.com - September 26 at 11:01 AM
News IconMylan Inc. CEO Heather Bresch Testifies on EpiPen Price Increases (NASDAQ:MYL)
tvlistings.zap2it.com - September 25 at 5:40 PM
marketrealist.com logoGenerics or Specialty: Which Mylan Segment Is Growing Fastest? (NASDAQ:MYL)
marketrealist.com - September 24 at 10:43 AM
barrons.com logo[$$] How Mylan Got the Market And Criticism It Deserves (NASDAQ:MYL)
www.barrons.com - September 24 at 10:43 AM
News IconMylan CEO Bresch’s pay irks lawmakers, investors (NASDAQ:MYL)
www.sltrib.com - September 23 at 5:53 PM
News IconMylan CEO defends EpiPen cost to angry lawmakers (NASDAQ:MYL)
canalcncarauca.com - September 23 at 5:53 PM
reuters.com logoParent bloggers question role in Mylan’s EpiPen schools push (NASDAQ:MYL)
www.reuters.com - September 23 at 5:53 PM
marketrealist.com logoTeva’s Valuation Multiples Compared to Other Generic Drug Players (NASDAQ:MYL)
marketrealist.com - September 23 at 5:53 PM
feeds.benzinga.com logoDeutsche Tweaking Its Mylan View Following CEO's Congressional Testimony (NASDAQ:MYL)
feeds.benzinga.com - September 23 at 4:55 PM
seekingalpha.com logoWhere Did All That EpiPen Money Go? - Seeking Alpha (NASDAQ:MYL)
seekingalpha.com - September 23 at 10:59 AM
News IconRep. Duckworth wants to know if the CEO of Mylan crossed the line by working with her mother to require EpiPens in ... - WGN Radio (NASDAQ:MYL)
wgnradio.com - September 23 at 10:59 AM
marketwatch.com logo5 things we still don’t know about EpiPen pricing after Mylan’s congressional beating (NASDAQ:MYL)
www.marketwatch.com - September 23 at 10:59 AM
News IconEven Elizabeth Warren’s fury can’t shame America’s CEOs (NASDAQ:MYL)
qz.com - September 23 at 10:59 AM
ft.com logo[$$] US politicians lament inaction over price-gouging drug companies (NASDAQ:MYL)
www.ft.com - September 23 at 10:59 AM
feeds.reuters.com logoParent bloggers question role in Mylan's EpiPen schools push (NASDAQ:MYL)
feeds.reuters.com - September 23 at 2:39 AM
News IconRep. Duckworth wants to know if the CEO of Mylan crossed the line by working with her mother to require EpiPens in schools? (NASDAQ:MYL)
wgnradio.com - September 22 at 6:00 PM
nydailynews.com logoEpiPen maker met with bipartisan outrage over 500% price hike (NASDAQ:MYL)
www.nydailynews.com - September 22 at 6:00 PM
News IconEpiPen maker CEO to seething lawmakers: We’re doing the world a favor (NASDAQ:MYL)
arstechnica.com - September 22 at 6:00 PM
foxnews.com logoLawmakers slam EpiPen maker for rising prices, as CEO downplays profits (NASDAQ:MYL)
www.foxnews.com - September 22 at 6:00 PM
News IconMylan's pay for CEO grates on lawmakers, investors (NASDAQ:MYL)
www.chicagobusiness.com - September 22 at 6:00 PM
finance.yahoo.com logoMylan CEO: Reformulating EpiPen to Have Longer Shelf Life (NASDAQ:MYL)
finance.yahoo.com - September 22 at 6:00 PM
News IconMylan CEO Infuriates Lawmakers At Hearing On EpiPen Costs - CBS Local (NASDAQ:MYL)
dfw.cbslocal.com - September 22 at 11:05 AM
News IconMylan CEO defends EpiPen cost increases to angry lawmakers - Chicago Tribune (NASDAQ:MYL)
www.chicagotribune.com - September 22 at 11:05 AM
thestreet.com logoMore Squawk From Jim Cramer: Mylan (MYL) Should Have Immediately Cut EpiPen Price (NASDAQ:MYL)
www.thestreet.com - September 22 at 11:05 AM
cnbc.com logoEmbattled EpiPen CEO draws fire over private jet use (NASDAQ:MYL)
www.cnbc.com - September 22 at 11:05 AM
feeds.benzinga.com logoControversy Pullback Offers Good Entry Point For Mylan (NASDAQ:MYL)
feeds.benzinga.com - September 22 at 10:58 AM
feeds.reuters.com logoUPDATE 2-U.S. lawmakers blast Mylan CEO over 'sickening' EpiPen price hikes (NASDAQ:MYL)
feeds.reuters.com - September 21 at 6:55 PM
News IconThe newest pharma villain Novum is charging $9,561 for a tube of skin cream (NASDAQ:MYL)
qz.com - September 21 at 5:57 PM
sg.finance.yahoo.com logoThe Latest: Cummings says Mylan hasn't provided EpiPen data (NASDAQ:MYL)
sg.finance.yahoo.com - September 21 at 5:57 PM

Social

Mylan (NASDAQ:MYL) Chart for Tuesday, September, 27, 2016


Last Updated on 9/27/2016 by MarketBeat.com Staff